Labcorp launches molecular residual disease and liquid biopsy solutions

Labcorp® plasma detect™ now available for clinical use to assess risk of recurrence in stage iii colon cancer patients fda-authorized liquid biopsy assay pgdx elio® plasma focus™ dx now available to support treatment selection burlington, n.c. , april 23, 2025 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: labcorp plasma detect for clinical use to help assess the risk of disease recurrence in stage iii colon cancer patients, and the availability of pgdx elio plasma focus dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the u.s. food and drug administration (fda) to identify patients who may benefit from targeted treatments.
LH Ratings Summary
LH Quant Ranking